

Healthcare & Life Sciences



AZB & Partners is the preferred counsel in the Healthcare & Life Sciences space. We advise several leading pharmaceutical, medical device, diagnostic and healthcare companies on a range of matters.

Our work includes:

- Advising on mergers and acquisitions, fund raising, business reorganisations and commercial contracting matters
- Advising on IP licensing and technical collaborations
- Auditing IP portfolios
- Advising on licensing requirements, pricing issues and clinical trials
- Advising on various ethical practices, including in relation to interactions with medical practitioners and compliance with advertising and marketing codes
- Handling trademark and patent portfolios of pharma and biotech companies
- Advising on IP enforcement proceedings



Pfizer on laws relating to the import, manufacture and sale of drugs, drug pricing, interactions with medical practitioners, technology licenses, research collaborations and supply agreements governing its active pharmaceutical ingredients and in relation to clinical trials.



India Medtronic on (i) licensing requirements for transferring stock of non-implantable medical devices to hospitals, as regulated under the Medical Device Rules, 2017; and (ii) issues relating to the price control of 'coronary stents.'



Novartis India with respect to the (i) implications of a common law license; and (ii) laws and regulations governing the online sale of drugs in India and interactions with medical practitioners.



Merck Sharp & Dohme on (i) licensing and supplying its pharmaceutical products and vaccines; (ii) managing its IP; and (iii) complying with regulatory requirements in India.



Bristol Myers Squibb with respect to (i) developing and securing its IP rights; and (ii) its agreements relating to a research partnership with Syngene, a wholly owned subsidiary of Biocon.



Natera on (i) license agreements for its gene sequencing technology; and (ii) laws relating to Good Clinical Practice Guidelines, clinical trials, interactions with investigators, biomedical research and export / shipment of biological samples outside India.



MDA Agree on (i) laws governing foreign physicians to collaborate and provide medical advice to patients based in India; and (ii) compliance requirements relating to the transfer of clinical information and pathological specimens from India to foreign jurisdictions.



Amneal Pharmaceuticals LLC on (i) developing and commercializing production of its active pharma ingredients; and (ii) managing its IP; and (iii) complying with Indian regulatory requirements.



Torrent Pharmaceuticals with respect to successfully enforcing its brand 'Chymoral Forte' against Wockhardt.



Nitto Denko on laws governing the import of medical devices into India and clinical trials, including clinical trial agreements, informed consent forms and adverse events reporting.



CooperVision on (i) its invoicing issues in India, in view of the new GST regime; (ii) its distribution related arrangements; and (iii) the data privacy issues relating to its third party payroll services agreement.



Abbott on the laws (i) governing its interactions with Indian medical practitioners; and (ii) pertaining to stent pricing and recall in India.



The Gates Foundation on the Indian regulations governing Genetically Modified Organisms and associated product liability risks.



Zimmer in relation to the laws and regulations governing the advertising and marketing of medical devices in India.



Boston Scientific India with respect to laws and regulations governing interactions with medical practitioners.



C.R. Bard on (i) the laws governing the import of medical devices into India; and (ii) interactions with medical practitioners.

Healthcare & Life Sciences



AZB & Partners is the preferred counsel in the Healthcare & Life Sciences sector. Our clients include Indian and international pharmaceutical, medical devices, and healthcare companies.

Our work includes:

- Advising on IP licensing and technical collaborations
- Auditing IP portfolios
- Advising on licensing requirements, pricing issues and clinical trials
- Advising on various ethical practices, including in relation to interactions with medical practitioners and compliance with advertising and marketing codes

Additionally, in conjunction with our market-leading corporate, regulatory, tax and competition practices, we regularly advise operators, as well as investors in the healthcare and life sciences sectors, on a range of transactional matters, including mergers and acquisitions, fund raising, business reorganisations and commercial contracting.



Glaxo SmithKline on its minority share acquisition in GlaxoSmithKline Consumer Healthcare for US\$ 690 million, pursuant to a voluntary offer made under the SEBI takeover regulations.



Pfizer on (i) the sale of its Capsugel business to KKR; and (ii) the global restructuring of its animal health business, including the divestment of its Indian animal health business.



KKR on (i) its 49.7% acquisition, through Radiant Life Care, of Max Healthcare Institute; (ii) its majority acquisition of Max India's allied health business; and (iii) its minority acquisition of Max Ventures Investment Holdings.



TPG Group with respect to its acquisition of a (i) minority stake in Manipal Health Enterprises, Manipal Group's healthcare arm, for US\$ 145.75 million; and (ii) majority stake in Cancer Treatment Services.



Actavis Pharma Group in relation to (i) its acquisition of the active pharmaceutical ingredient manufacturing division of Sanmar Specialty Chemicals; and (ii) the sale of its API facility Nuray Chemicals.



Famy Care ('FCL'), its shareholders and Jai Pharma ('JPL') on the (i) demerger of its female contraceptive business into JPL; and (ii) US\$ 800 million sale of JPL by FPL's existing shareholders to Mylan Laboratories.



The Dabur Group on (i) its acquisition of a stake in several companies, such as the Balsara Group and Fem Care Pharma; (ii) IFC's PE investment in Dabur Pharma; and (iii) the sale of its non-oncology formulations business to Alembic.



Max Healthcare Institute on (i) Warburg Pincus' PE investment in Max India and Max Healthcare; (ii) its JV with Nova Medical Centres for day care surgical centers; and (iii) its 51% acquisition of Saket City Hospitals from Smart Health City.



The Kemwell Group, including its promoters, on the sale of its pharma contract development and manufacturing business in India, US and Sweden, to Recipharm AB.



Claris Lifesciences on the transfer of its infusion business for India and emerging markets to its joint venture company with Otsuka Pharmaceutical Factory and Mitsui for US\$ 170 million.



Ascent Health and Wellness Solutions on Evermed Holdings' subscription of approximately 55% of its share capital for US\$ 60 million.



RHT Health Trust Manager on the sale of its Indian portfolio of 12 clinical establishments, 4 greenfield clinical establishments and 2 operating hospitals to Fortis Healthcare, its ultimate sponsor.



The Davita Group with respect to (i) its acquisition and subsequent sale of Nephrolife Care (India); and (ii) its 49% acquisition of Express Clinics.



Leapfrog Investments on its acquisition of a controlling stake in Ascent Meditech, a leading Indian manufacturer of medical devices and healthcare products.



The CDC Group on its minority acquisition of Narayana Hrudayalaya, for US\$ 50 million.



Krishna Institute of Medical Sciences ('KIMS'), a leading private healthcare provider in Southern India, on General Atlantic's US\$ 130 million equity investment in KIMS.